Aminotransferase elevation in HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs

Mamta K. Jain, Nimisha K. Parekh, Jill Hester, William M. Lee

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Discerning drug hepatotoxicity from viral hepatitis flares remains an ongoing problem unique to patients coinfected with HIV and hepatitis B (HBV). We present three such coinfected patients who have been on two anti-HBV agents, lamivudine and tenofovir disoproxil fumarate simultaneously, as part of highly active antiretroviral therapy (HAART). All three developed significant aminotransferase elevations 6-12 weeks after initiation of HAART despite being on two active HBV drugs. Two of the three patients were initially thought to have drug-related hepatotoxicity from HIV medications. It seems more likely that all three patients demonstrated hepatitis B reactivation of differing severity as the result of varying degrees of immune recovery. Distinguishing clearly between drug-related hepatotoxicity and hepatitis reactivation may be difficult but is important as their clinical management differs.

Original languageEnglish (US)
Pages (from-to)817-822
Number of pages6
JournalAIDS Patient Care and STDs
Volume20
Issue number12
DOIs
StatePublished - Dec 2006

Fingerprint

Transaminases
Hepatitis B virus
HIV
Tenofovir
Highly Active Antiretroviral Therapy
Hepatitis B
Pharmaceutical Preparations
Hepatitis
Lamivudine

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Leadership and Management
  • Nursing(all)

Cite this

Aminotransferase elevation in HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs. / Jain, Mamta K.; Parekh, Nimisha K.; Hester, Jill; Lee, William M.

In: AIDS Patient Care and STDs, Vol. 20, No. 12, 12.2006, p. 817-822.

Research output: Contribution to journalArticle

@article{9edc5002b2f547c4aa89e0aa51876d82,
title = "Aminotransferase elevation in HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs",
abstract = "Discerning drug hepatotoxicity from viral hepatitis flares remains an ongoing problem unique to patients coinfected with HIV and hepatitis B (HBV). We present three such coinfected patients who have been on two anti-HBV agents, lamivudine and tenofovir disoproxil fumarate simultaneously, as part of highly active antiretroviral therapy (HAART). All three developed significant aminotransferase elevations 6-12 weeks after initiation of HAART despite being on two active HBV drugs. Two of the three patients were initially thought to have drug-related hepatotoxicity from HIV medications. It seems more likely that all three patients demonstrated hepatitis B reactivation of differing severity as the result of varying degrees of immune recovery. Distinguishing clearly between drug-related hepatotoxicity and hepatitis reactivation may be difficult but is important as their clinical management differs.",
author = "Jain, {Mamta K.} and Parekh, {Nimisha K.} and Jill Hester and Lee, {William M.}",
year = "2006",
month = "12",
doi = "10.1089/apc.2006.20.817",
language = "English (US)",
volume = "20",
pages = "817--822",
journal = "AIDS Patient Care and STDs",
issn = "1087-2914",
publisher = "Mary Ann Liebert Inc.",
number = "12",

}

TY - JOUR

T1 - Aminotransferase elevation in HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs

AU - Jain, Mamta K.

AU - Parekh, Nimisha K.

AU - Hester, Jill

AU - Lee, William M.

PY - 2006/12

Y1 - 2006/12

N2 - Discerning drug hepatotoxicity from viral hepatitis flares remains an ongoing problem unique to patients coinfected with HIV and hepatitis B (HBV). We present three such coinfected patients who have been on two anti-HBV agents, lamivudine and tenofovir disoproxil fumarate simultaneously, as part of highly active antiretroviral therapy (HAART). All three developed significant aminotransferase elevations 6-12 weeks after initiation of HAART despite being on two active HBV drugs. Two of the three patients were initially thought to have drug-related hepatotoxicity from HIV medications. It seems more likely that all three patients demonstrated hepatitis B reactivation of differing severity as the result of varying degrees of immune recovery. Distinguishing clearly between drug-related hepatotoxicity and hepatitis reactivation may be difficult but is important as their clinical management differs.

AB - Discerning drug hepatotoxicity from viral hepatitis flares remains an ongoing problem unique to patients coinfected with HIV and hepatitis B (HBV). We present three such coinfected patients who have been on two anti-HBV agents, lamivudine and tenofovir disoproxil fumarate simultaneously, as part of highly active antiretroviral therapy (HAART). All three developed significant aminotransferase elevations 6-12 weeks after initiation of HAART despite being on two active HBV drugs. Two of the three patients were initially thought to have drug-related hepatotoxicity from HIV medications. It seems more likely that all three patients demonstrated hepatitis B reactivation of differing severity as the result of varying degrees of immune recovery. Distinguishing clearly between drug-related hepatotoxicity and hepatitis reactivation may be difficult but is important as their clinical management differs.

UR - http://www.scopus.com/inward/record.url?scp=33846218669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846218669&partnerID=8YFLogxK

U2 - 10.1089/apc.2006.20.817

DO - 10.1089/apc.2006.20.817

M3 - Article

C2 - 17192146

AN - SCOPUS:33846218669

VL - 20

SP - 817

EP - 822

JO - AIDS Patient Care and STDs

JF - AIDS Patient Care and STDs

SN - 1087-2914

IS - 12

ER -